Abstract
We investigated the role of nitric oxide (NO) in inflammatory hyperalgesia. Coinjection of prostaglandin E2(PGE2) with the nitric oxide synthase (NOS) inhibitorNG-methyl-l-arginine (l-NMA) inhibited PGE2-induced hyperalgesia.l-NMA was also able to reverse that hyperalgesia. This suggests that NO contributes to the maintenance of, as well as to the induction of, PGE2-induced hyperalgesia. Consistent with the hypothesis that the NO that contributes to PGE2-induced sensitization of primary afferents is generated in the dorsal root ganglion (DRG) neurons themselves, l-NMA also inhibited the PGE2-induced increase in tetrodotoxin-resistant sodium current in patch-clamp electrophysiological studies of small diameter DRG neurons in vitro. Although NO, the product of NOS, often activates guanylyl cyclase, we found that PGE2-induced hyperalgesia was not inhibited by coinjection of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), a guanylyl cyclase inhibitor. We then tested whether the effect of NO depended on interaction with the adenylyl cyclase–protein kinase A (PKA) pathway, which is known to mediate PGE2-induced hyperalgesia.l-NMA inhibited hyperalgesia produced by 8-bromo-cAMP (a stable membrane permeable analog of cAMP) or by forskolin (an adenylyl cyclase activator). However, l-NMA did not inhibit hyperalgesia produced by injection of the catalytic subunit of PKA. Therefore, the contribution of NO to PGE2-induced hyperalgesia may occur in the cAMP second messenger pathway at a point before the action of PKA.
We next performed experiments to test whether administration of exogenous NO precursor or donor could mimic the hyperalgesic effect of endogenous NO. Intradermal injection of either the NOS substratel-arginine or the NO donor 3-(4-morphinolinyl)-sydnonimine hydrochloride (SIN-1) produced hyperalgesia. However, this hyperalgesia differed from PGE2-induced hyperalgesia, because it was independent of the cAMP second messenger system and blocked by the guanylyl cyclase inhibitor ODQ. Therefore, although exogenous NO induces hyperalgesia, it acts by a mechanism different from that by which endogenous NO facilitates PGE2-induced hyperalgesia. Consistent with the hypothesis that these mechanisms are distinct, we found that inhibition of PGE2-induced hyperalgesia caused by l-NMA could be reversed by a low dose of the NO donor SIN-1. The following facts suggest that this dose of SIN-1 mimics a permissive effect of basal levels of NO with regard to PGE2-induced hyperalgesia: (1) this dose of SIN-1 does not produce hyperalgesia when administered alone, and (2) the effect was not blocked by ODQ.
In conclusion, we have shown that low levels of NO facilitate cAMP-dependent PGE2-induced hyperalgesia, whereas higher levels of NO produce a cGMP-dependent hyperalgesia.
- hyperalgesia
- nitric oxide
- pain
- primary afferent nociceptor
- prostaglandin E2
- protein kinase A
- tetrodotoxin-resistant sodium current
Tissue injury results in hyperalgesic pain (tenderness), probably the most common presenting clinical symptom. This important phenomenon is believed to be attributable, in great part, to sensitization of primary afferent nociceptors so that they respond at a lower stimulus intensity and with greater number of action potentials. Inflammatory mediators have been implicated in producing this sensitization and hyperalgesia. Of these, prostaglandins are well established as mediators of mechanical hyperalgesia in both animals and humans (Collier and Schneider, 1972;Moncada et al., 1975; Ferreira et al., 1978) and of sensitization of primary afferent nociceptors (Martin et al., 1987; Schaible and Schmidt, 1988; Davis et al., 1993; Rueff and Dray, 1993). The inflammatory mediator prostaglandin E2(PGE2) is thought to act directly on the peripheral terminals of primary afferent nociceptors to produce hyperalgesia (Taiwo and Levine, 1989), to sensitize nociceptors in vitro(England et al., 1996; Gold et al., 1996a), and to enhance tetrodotoxin-resistant voltage-gated sodium current (TTX-R INa). Previous work in our laboratory suggests that PGE2-induced sensitization of nociceptors is mediated by the adenylyl cyclase–cAMP–protein kinase A (PKA) second messenger system. For example, agents that inhibit adenylyl cyclase, as well as those that inhibit PKA, attenuate PGE2-induced hyperalgesia (Taiwo and Levine, 1989, 1991; Khasar et al., 1995). PGE2 is a key mediator of inflammatory hyperalgesia.
A number of observations suggest that in the periphery nitric oxide (NO) also acts as a pronociceptive mediator (Moulton, 1996; Robbins and Grisham, 1997; Wallace and Chin, 1997). Intracutaneous injections of NO precursors evoke pain in humans (Houlthusen and Arndt, 1994, 1995). That NO is generated within nociceptors is suggested by these observations: (1) neuronal nitric oxide synthase-like immunoreactivity (nNOS-LI) is expressed in small- and medium-diameter dorsal root ganglion (DRG) neurons in rat and monkey (Zhang et al., 1993; Qian et al., 1996); (2) NADPH–diaphorase activity (Vanhatalao et al., 1996) and nNOS-LI (Zhang et al., 1993; Majewski et al., 1995) are colocalized in some DRG neurons with substance P-LI (SP-LI) and calcitonin gene-related peptide-LI (CGRP-LI); and (3) NOS-LI is coexpressed in some DRG neurons with CGRP-LI or SP-LI (Zhang et al., 1993) and is greatly reduced in DRG neurons in neonatal rats treated with capsaicin (Ren and Ruda, 1995). NO is considered to play a role in the induction of nociception, because NOS-LI in lumbar DRG neurons is increased by noxious irritation of the bladder (Vizzard et al., 1996), by noxious stimulation with resiniferatoxin (Farkas-Szallasi et al., 1995; Vizzard et al., 1995), and by induction of neuropathic models of pain using sciatic nerve transection (Fiallos-Estrada et al., 1993;Zhang et al., 1993; Beesley, 1995) or by ligation of lumbar dorsal roots (Choi et al., 1996) or nerves (Steel et al., 1994). NO also contributes to withdrawal hyperalgesia in rats made tolerant to opioid-induced peripheral antinociception (Aley and Levine, 1997a,b). Furthermore, the NOS inhibitorNG-methyl-l-arginine (l-NMA) suppresses activity in lumbar dorsal roots originating from a sciatic neuroma (Wiesenfeld-Hallin et al., 1993).l-NMA also reduces thermal hyperalgesia produced by chronic constriction injury of the sciatic nerve or hindpaw inflammation (Moore et al., 1993; Thomas et al., 1996; Lawand et al., 1997). Clearly, there is abundant evidence that NO plays a role in nociceptive signaling. When studying NO, it is important to evaluate cGMP, because NO stimulates guanylyl cyclase, and many of the cellular effects of NO are the result of NO-induced increases in the level of cGMP (Jaffrey and Snyder, 1995). NO-donating compounds stimulate marked elevation of cGMP levels in cultured rat DRG neurons (Dymshitz and Vasko, 1994), and activation of NOS by the algesic agent bradykinin increases cGMP in rat DRG neurons (Harvey and Burgess, 1996).
Because interactions between inflammatory mediators have been reported and because there are interactions at the second messenger level, it is important to evaluate whether NO contributes to the prototype hyperalgesia and sensitization produced by PGE2. In this study, therefore, we tested such a contribution by NO to hyperalgesia produced by the inflammatory mediator PGE2, and we investigated mechanisms underlying the induction of hyperalgesia by NO, which have not been well delineated.
MATERIALS AND METHODS
Animals. Experiments were performed on male Sprague Dawley rats (200–250 gm; Bantin-Kingman, Fremont, CA). Animals were housed in groups of two under a 12 hr light/dark cycle. Food and water were available ad libitum. All behavioral testing was done between 10:00 A.M. and 4:00 P.M. Experiments were performed with the approval of the Institutional Animal Care Committee of the University of California at San Francisco.
Behavioral testing. The nociceptive flexion reflex was quantified with a Basil analgesymeter (Stoelting, Chicago, IL), which applies a linearly increasing mechanical force to the dorsum of the rat’s hindpaw. Before the experiments, rats were exposed to the paw-withdrawal testing procedure for 3 hr (1 hr/d for 3 d). On the day of the experiment, rats were exposed to the same procedure for 1 hr, and the baseline threshold was determined as the mean of the six readings before the administration of the test agent (Aley and Levine, 1997a,b). The mean ± SEM baseline threshold before treatments for the rats used in these experiments was 108.0 ± 0.4 gm (n = 260). Mechanical threshold was redetermined at three time points (15, 20, and 25 min) after administration of a hyperalgesic agent. The mean of these three readings was considered to be the paw-withdrawal threshold because of hyperalgesic agent administration, and this value was used to calculate the percentage change from the baseline threshold for each paw. To determine the timing of onset of action of the hyperalgesic agents, the mechanical threshold was also measured at 1 min intervals for 5 min after their administration, whereas the time course was determined by measuring the mechanical threshold at 30–60 min intervals for 2–4 hr.
Drug administration. The following drugs used in this study were obtained from Sigma (St. Louis, MO): PGE2,l-arginine (l-Arg), d-arginine (d-Arg), l-NMA,NG-methyl-d-arginine (d-NMA), 8-bromo-cAMP, and 3-morpholino-sydnonimine (SIN-1). Forskolin, 2-p-(2-carboxyethyl)phenethylamino-5′-N-ethylcarboxamido adenosine HCl (CGS21680), and (±)-2-dipropylamino-8-hydroxy-1,2,3,4-tetrahydronaphthalene HBr (8-OH-DPAT) were obtained from Research Biochemicals (Natick, MA). WIPTIDE was obtained from Peninsula Laboratories (Belmont CA), and 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) and protein kinase A catalytic subunit (PKACS) were obtained from Calbiochem (La Jolla, CA). The selection of the drug doses used in this study was based on dose–response curves determined during this and previous studies (Aley and Levine, 1997a,b). The stock solution of PGE2 (1 μg/2.5 μl) was prepared in 10% ethanol, and further dilutions were made in saline; the final concentration of ethanol was ≤1%. 8-bromo-cAMP, l-NMA, d-NMA, PKACS, and WIPTIDE were dissolved in saline. ODQ was dissolved in DMSO and diluted with saline (final concentration of DMSO, 10%). CGS21680 and 8-OH-DPAT were dissolved in deionized water. All drugs administered intradermally were in a volume of 2.5 μl/paw. For test agents with low cell membrane permeability (i.e., WIPTIDE and PKACS), 2 μl of distilled water was coinjected first, in the same syringe as the test agent to produce hypo-osmotic shock and thus facilitate cell permeability (Taiwo and Levine, 1989; Khasar et al., 1995). When drug combinations were used, they were administered from the same syringe in such a way that the drug mentioned first reached the intradermal site first. Such combinations of agents were separated in the syringe by a small air bubble to prevent their mixing in the syringe. Whenever an inhibitor was included, it was injected first.
Cell culture and in vitro electrophysiology.Primary cultures of adult rat lumbar DRG neurons were prepared as described previously (Gold et al., 1996b). Culture medium consisted of minimal essential medium [University of California at San Francisco (UCSF) Cell Culture Facility] with 10% fetal bovine serum (Life Technologies, Gaithersburg, MD) and 1000 U/ml each penicillin and streptomycin (UCSF Cell Culture Facility). Ganglia were dissected free, desheathed in cold culture medium, and then incubated for 2 hr at 37°C in culture medium with 0.125% collagenase. After an additional 10 min digestion in 0.25% trypsin, cells were mechanically dispersed by trituration with a fire-polished Pasteur pipette. Cells were plated onto glass coverslips coated with laminin (Life Technologies) and poly-dl-ornithine (Sigma) and were maintained in culture medium with nerve growth factor (Life Technologies) at 37°C under 3% CO2. Neurons were used within 24 hr of plating before appreciable outgrowth of neurites at a time when small diameter (20–30 μm) neuronal cell bodies express properties of nociceptors (Gold et al., 1996b). Drugs were added via the bath, which continuously perfused the recording chamber at 1–2 ml/min. Experiments were performed at room temperature (21–24°C).
Whole-cell patch-clamp recordings were performed on small diameter (<30 μm) neurons in 1-d-old cultures of dissociated DRGs from adult rats, using an Axopatch 200B amplifier with pClamp6 acquisition and stimulation programs (Axon Instruments, Foster City, CA). Data were low-pass-filtered at 5 kHz and acquired at a sampling rate of 10 kHz.
Voltage-clamp experiments were performed with 2–5 MΩ electrodes filled with (in mm): CsCl 140, NaCl 10, CaCl20.1, MgCl2 2, EGTA 11, HEPES 10, MgATP 2, and LiATP 1, pH adjusted to 7.2 with Tris base. Bath consisted of (in mm): NaCl 35, tetraethylammonium chloride 30, choline chloride 65, CaCl2 0.5, MgCl2 5, HEPES 10, and glucose, pH adjusted to 7.4 with NaOH, and osmolality adjusted to 325 mOsm with sucrose. Tetrodotoxin (50 nm) was added to the bath. Capacitance and series resistance was compensated (>80%), and leak subtraction was performed with a P/4 protocol. After obtaining a current–voltage relationship for TTX-R INa, a 25 msec depolarizing test pulse was applied every 20 sec to monitor the size of the current during the experiment. A voltage that produced approximately half of the maximal current activation was used for the test pulse, because the greatest increase in TTX-R INa produced by PGE2 is seen at this part of the current–voltage relationship. Experimental and control neurons were studied alternately on the same day for each comparison.
Statistical analysis. Data are presented as mean ± SEM; statistical significance was determined by ANOVA followed by Scheffe’s post hoc test; and p < 0.05 was considered statistically significant.
RESULTS
l-NMA, but not ODQ, blocks PGE2 hyperalgesia
We first determined whether NO contributes to PGE2-induced hyperalgesia and whether guanylyl cyclase is involved (Fig. 1). Injection ofl-NMA (1 μg), a competitive NOS inhibitor, preceding PGE2 in the same syringe significantly attenuated PGE2-induced hyperalgesia to mechanical stimuli (p < 0.05). Injection of l-NMA (1 μg) 5 min after PGE2, when hyperalgesia is already well established (Ouseph et al., 1995), significantly reversed hyperalgesia. l-NMA alone had no effect on mechanical nociceptive threshold. The inactive stereoisomer of l-NMA,d-NMA (10 μg), was without effect on PGE2-induced hyperalgesia. Injection of the guanylyl cyclase inhibitor ODQ (1 μg) before PGE2 had no effect.
Reduction of mechanical nociceptive threshold (hyperalgesia) produced by PGE2 15 min after injection (PGE2) (100 ng; n = 12),l-NMA (1 μg; n = 6) plus PGE2 ( l-NMA/PGE2) (n = 12; p < 0.05), PGE2 5 min after injection [PGE2(5′)] (n = 6), l-NMA 5 min after PGE2 (PGE2/l-NMA5′post) (n = 6; p < 0.05),d-NMA (10 μg) plus PGE2( d-NMA/PGE2) (n = 6), ODQ (1 μg) plus PGE2 (ODQ/PGE2) (n = 6), and l-NMA(n = 6) on mechanical paw-withdrawal threshold in rats. In this and subsequent figures, *p < 0.05. Higher values indicate greater hyperalgesia. The data for one behavioral experimental group, PGE2, is repeated in more than one figure for ease of comparison.
l-NMA inhibits PGE2-induced potentiation of TTX-R Inain vitro
PGE2 sensitizes cultured small diameter DRG neurons and potentiates TTX-R INa (England et al., 1996; Gold et al., 1996a). We tested whether endogenous NO derived from the primary afferent is necessary for potentiation of TTX-R INa by PGE2. One hundred micromolar l-NMA (n = 15) or d-NMA (n = 14) was added to the extracellular bath for 15 min before the application of 1 μm PGE2. The mean PGE2-induced increase in the size of peak TTX-R INa elicited by a depolarizing voltage step was significantly smaller in the cells treated with l-NMA than in those treated with d-NMA (p < 0.05) (Fig. 2).
l-NMA reduces the PGE2-induced potentiation of TTX-R INa. TTX-R INa was monitored by test pulses given every 20 sec. Voltage of the test pulse (−20 to −5 mV) was selected for each neuron to give an approximately half-maximal current amplitude. One hundred micromolar d-NMA or l-NMA was included in the bath for 15 min before exposure to 1 μm PGE2. PGE2 typically causes a potentiation of TTX-R INa in approximately half of cells tested (Gold et al., 1996a,b). Experiments were alternated between using the active and inactive enantiomers of the NOS inhibitor, and data from all neurons were used, including those in which the current was not affected by PGE2. Peak current amplitudes were normalized to mean of the baseline measurements.
l-NMA blocks hyperalgesia induced by CGS21680 and 8-OH-DPAT
We tested whether NOS activity is required to produce hyperalgesia induced by other peripherally acting hyperalgesic agents. As shown previously (Taiwo and Levine, 1989, 1990, 1991; Taiwo et al., 1992), the intradermal injection of CGS21680 (A2adenosine receptor agonist; 1 μg) and 8-OH-DPAT (5HT1Aserotonergic agonist; 1 μg) produced mechanical hyperalgesia (Fig.3). Injection of l-NMA (1 μg) with CGS21680 and 8-OH-DPAT significantly attenuated the resulting hyperalgesia (p < 0.05) (Fig. 3), similar to its effect on PGE2-induced hyperalgesia.
Reduction of the paw-withdrawal threshold by the A2 adenosine agonist CGS21680 after injection (1 μg; n = 6), l-NMA plus CGS21680 ( l-NMA/CGS) (n= 6; p < 0.05), 5HT1A agonist8-OH-DPAT after injection (1 μg; n= 6), and l-NMA plus 8-OH-DPAT ( l-NMA/8-OH) (n = 6; p < 0.05) on mechanical paw-withdrawal threshold in rats.
l-NMA blocks hyperalgesia induced by 8-bromo-cAMP and forskolin but not by PKACS
To determine whether the contribution of NO to hyperalgesia is attributable to interaction of NO with the cAMP second messenger system and at what level in the cAMP second messenger pathway NO is required, we evaluated the effect of l-NMA on the hyperalgesia produced by different components of the pathway. Five minutes after the intradermal injection of 8-bromo-cAMP (10 μg), forskolin (10 μg), or PKACS (the catalytic subunit of PKA; 15 U), near-maximal mechanical hyperalgesia was present. Injection of l-NMA (1 μg) before 8-bromo-cAMP and forskolin, but not PKACS, resulted in reduced hyperalgesia (Fig. 4). Injection of WIPTIDE inhibited PKACS hyperalgesia, as it did 8-bromo-cAMP and forskolin hyperalgesia, which indicates that the isolated catalytic subunit of PKA appears to produce hyperalgesia through the same catalytic action as PKA.
Reduction of the paw-withdrawal threshold by forskolin (10 μg) 5 min after injection (Forsk) (n = 8), l-NMA plus forskolin ( l-NMA/Forsk) (n = 6;p < 0.05), WIPTIDE plus forskolin (WIPTIDE/Forsk) (n = 10;p < 0.05), 8-bromo-cAMP after injection (8brcAMP) (1 μg; n = 12),l-NMA plus 8-bromo-cAMP ( l-NMA/8brcAMP) (n = 8;p < 0.05), WIPTIDE plus 8-bromo-cAMP (WIPTIDE/8brcAMP) (n = 6;p < 0.05), PKACS (15 U;n = 12), WIPTIDE plus PKACS (WIPTIDE/PKACS) (n = 6;p < 0.05), and l-NMA plus PKACS ( l-NMA/PKACS) (n = 6; not statistically significant) on mechanical paw-withdrawal threshold in rats.
Administration of NO donor or precursor induces hyperalgesia
As shown in Figure 5, Aand D, intradermal injection of the NOS substratel-Arg (10 ng to 10 μg) or the NO donor SIN-1 (10 ng to 40 μg) caused a dose-dependent decrease in the paw-withdrawal threshold. This hyperalgesia was inhibited by the guanylyl cyclase inhibitor ODQ but was unaffected by the PKA inhibitor WIPTIDE (Fig.6A). This hyperalgesic action of NO contrasts with the guanylyl cyclase-independent mechanism by which NO facilitates PGE2-induced hyperalgesia (Fig.6B). In control experiments, d-Arg did not induce hyperalgesia (Fig. 6A).
A, Dose–response curve forl-Arg-induced hyperalgesia (n = 6).B, Latency to onset of l-Arg-induced (10 μg) mechanical hyperalgesia (n = 6).C, Time course of l-Arg-induced mechanical hyperalgesia (n = 6). D, Dose–response curve of SIN-1-induced hyperalgesia (n = 6). E, Latency to onset of SIN-1-induced hyperalgesia (10 μg; n = 6).F, Time course of SIN-1-induced hyperalgesia (n = 8).
A, Change in mechanical paw withdrawal after injection of l-Arg ( l-Arg) (10 μg; n = 12), ODQ plus l-Arg (ODQ/l-Arg) (n = 6), WIPTIDE plus l-Arg (WIPTIDE/l-Arg) (n = 6),l-NMA plus l-Arg ( l-NMA/l-Arg) (n = 6), d-NMA/l-Arg (n = 6), d-Arg ( d-Arg) (10 μg; n = 6), PGE2 (PGE2) (n = 12), WIPTIDE plus PGE2 (WIPTIDE/PGE2) (n = 12), ODQ plus PGE2(ODQ/PGE2) (n = 8),SIN-1 (10 μg; n = 6), ODQ plus SIN-1 (ODQ/SIN) (n = 8), and WIPTIDE plus SIN-1 (WIPTIDE/SIN) (n = 6). B, Change in mechanical paw-withdrawal threshold after injection of PGE2(n = 12), l-NMA plus PGE2( l-NMA/PGE2) (n = 6), SIN-1 (SIN) (100 ng; n = 6), and l-NMA plus ODQ plus PGE2 plus SIN-1 ( l-NMA/ODQ/PGE2/SIN) (100 ng;n = 12).
Exogenous sources of NO can reconstitute the facilitatory effect of endogenous NO on PGE2-induced hyperalgesia
We tested whether NO from exogenous sources can mimic the ability of endogenous NO to facilitate PGE2-induced hyperalgesia. To inhibit endogenous NO production, l-NMA was coinjected into the paw with PGE2, which reduced the PGE2-induced decrease in paw-withdrawal threshold by ∼62% (Fig. 1). As shown in Figure 6B, coinjection of the NO donor compound SIN-1 with l-NMA and PGE2 restored the PGE2-induced decrease in paw-withdrawal threshold to a value similar to that observed when endogenous NOS was not inhibited (i.e., in the absence ofl-NMA). The 100 ng dose of SIN-1 that facilitated PGE2-induced hyperalgesia was insufficient to induce hyperalgesia by itself (Fig. 5D). To further preclude the possibility that NO-induced (cGMP-dependent) hyperalgesia played a role in this reconstitution experiment, the guanylyl cyclase inhibitor ODQ was coinjected with PGE2, l-NMA, and SIN-1.
DISCUSSION
In this study, we found that NO, but not cGMP, contributes to initiation and maintenance of hyperalgesia and sensitization produced by the inflammatory mediator PGE2. We also found that the independent hyperalgesia produced by NO depends on cGMP and may require a higher concentration than that for facilitation of PGE2hyperalgesia and sensitization. The reduction in PGE2-induced potentiation of TTX-R INa inl-NMA treated cells parallels the effect ofl-NMA on PGE2-induced hyperalgesia, suggesting that both phenomena depend on NO for full expression and that cells other than the one being recorded from are not required for these effects of PGE2 or NO. Although many effects of NO have been reported to be mediated by guanylyl cyclase activity (Jaffrey and Snyder, 1995), we observed that the guanylyl cyclase inhibitor ODQ had no effect on PGE2-induced hyperalgesia, suggesting that facilitation of PGE2-induced hyperalgesia by NO and the other mechanisms of PGE2-induced hyperalgesia do not involve NO signaling through guanylyl cyclase.
Additional experiments attempted to determine where NO might act to facilitate PGE2 hyperalgesia. Evidence suggests that initiation of PGE2-induced hyperalgesia is attributable to action of PGE2 at an E-type prostaglandin receptor on the primary afferent nociceptor terminal, activation of a stimulatory G-protein which then activates adenylyl cyclase, followed by an increase in the level of cAMP and activation of PKA (Taiwo and Levine, 1989, 1991; Khasar et al., 1995). We observed that hyperalgesia produced by 8-bromo-cAMP (which activates PKA) and forskolin (which activates adenylyl cyclase) was attenuated by l-NMA in a manner similar to the effect of l-NMA on PGE2hyperalgesia, but that in contrast, hyperalgesia produced by injection of PKACS (to mimic activity of endogenous PKA) was not affected byl-NMA. These results suggest that NO might be required for activation of PKA after administration of PGE2. Of note, others have shown that NO can modulate activity of kinases (Gopalakrishna et al., 1993; Burgstahler and Nathanson, 1995; Studer et al., 1996; Minamino et al., 1997). The fact that l-NMA inhibited hyperalgesia induced by two other direct-acting hyperalgesic agents (CGS21680, an A2 adenosine receptor agonist, and 8-OH-DPAT, a 5HT1A serotonin receptor agonist) suggests that dependence on NO is a general feature of hyperalgesia induced via the cAMP second messenger system.
Additional experiments revealed that there was an independent NO-induced hyperalgesia that depended on the cGMP second messenger pathway and not on the cAMP pathway (Fig. 6B). We hypothesize that a relatively low level of NO can facilitate cAMP-dependent hyperalgesia induced by PGE2 and other inflammatory mediators, whereas stimulated increases in NO to higher levels might be required to induce the cGMP-dependent hyperalgesia. Supporting this hypothesis, when endogenous NO production was blocked, the level of NO donor required to facilitate PGE2-induced hyperalgesia was at least an order of magnitude lower than the level required for NO to induce hyperalgesia by itself. However, it is not possible to know whether exogenous NO has ready access to the necessary sites. Also, we cannot determine from our data whether basal levels of constitutively synthesized NO are sufficient to facilitate PGE2-induced hyperalgesia or whether PGE2stimulates synthesis of NO (to a level lower than that required to induce cGMP-dependent hyperalgesia). However, it appears that constitutive synthesis of NO does not affect baseline nociceptive threshold, because inhibition of NOS does not alter paw-withdrawal threshold. Finally, although our in vitro patch-clamp data imply that the NO that facilitates PGE2-induced hyperalgesia is synthesized in DRG neurons and acts on DRG neurons, our data do not determine the site of action for cGMP-dependent NO-induced hyperalgesia. Clearly, further study is needed to determine concentration and site requirements for the two distinct effects of NO that we have evaluated.
NO is generated in significant concentrations at sites of inflammation in which multiple hyperalgesic inflammatory mediators, such as PGE2, adenosine, or serotonin, are also produced. Although the evidence for a role of NO in clinical pain is limited, NO may facilitate the hyperalgesia induced by those mediators using the cAMP second messenger pathway and may also have an independent cGMP-dependent hyperalgesic effect. If both of these contributions are clinically significant, different therapies for these two distinct mechanisms of NO may be needed for successful pharmacological treatment of inflammatory pain.
Footnotes
This work was supported by National Institutes of Health Grant NS21647. We thank Dr. David Bredt for many discussions about NO/cGMP signaling and Drs. David Reichling and Kimberly Tanner for their careful scrutiny of this manuscript.
Correspondence should be addressed to Dr. Jon D. Levine, National Institutes of Health Pain Center (UCSF), C-522 Box 0452, University of California at San Francisco, San Francisco, CA 94143-0452.
